unknown
Stage
About
Brink Biologics develops and licenses proprietary NK-92 natural killer cell lines and associated assays for use in antibody-dependent cellular cytotoxicity (ADCC) testing and related immunological research and therapeutic development.
Explore Brink Biologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.